Outcomes at ≥ 4 weeks | Number of studies (n) | SMD (95% CI) |
---|---|---|
*SMD = standardised mean difference; minus sign means results favour the dry powder inhaler. A fixed effects model was used. | ||
FEV1 | 7 (1404) | –0.14 (–0.25 to –0.03) |
Morning peak expiratory flow rate | 7 (1389) | –0.14 (–0.25 to –0.04) |
Use of additional relief drugs | 6 (967) | –0.18 (–0.31 to –0.05) |